Our R&D Activity Areas

  • Home
  • Our R&D Activity Areas
Our R&D Activity Areas

Our R&D Activity Areas

R&D and Innovation Overview – Eliz Pharmaceuticals & Serum / Çetinkaya Pharmaceuticals

As Eliz İlaç ve Serum, together with our strategic subsidiary Çetinkaya Pharmaceuticals, we proudly serve the healthcare industry as one of Turkey’s rising R&D centers, supported by advanced technological infrastructure, innovative drug development capabilities, and strong academic collaborations. Our R&D team consists of 20 expert scientists, and all research activities are conducted within a multidisciplinary structure.

Çetinkaya Pharmaceuticals continues its R&D operations across a broad portfolio ranging from conventional pharmaceutical products to biotechnological molecules, from viral and bacterial vaccine technologies to anti-serum development platforms.

Our R&D Activity Areas 

1. Conventional Pharmaceuticals

  • Sterile parenteral solutions
  • IV fluids
  • Emergency intervention products
  • Customized formulation development
Activities include stability studies, pharmaceutical technology development, process optimization, and pilot-scale manufacturing validation.

2. Biotechnological Products

  • Insulin group biotechnological products
  • Monoclonal antibodies
  • Recombinant proteins
  • Biosimilar & biobetter development projects
Comprehensive characterization, biosimilarity assessments, and advanced molecular biology testing—fully compliant with EMA/FDA standards—are conducted within our in-house laboratories.

3. Vaccine and Anti-Serum Technologies

  • Viral and bacterial vaccine platforms
  • Antitoxins and immunoglobulin products
  • Hyperimmune serum development
Safe immunization, toxin preparation, purification, and downstream processing are performed in a fully GMP-compliant infrastructure.

University Partnerships and Collaborative Research Programs

Çetinkaya Pharmaceuticals and Laboratories carry out R&D activities in strategic collaboration with leading universities and research institutions in Türkiye. Within this framework, we engage in:
  • Joint research and development projects
  • Master’s and PhD thesis support programs
  • Shared laboratory and instrumentation access
  • TÜBİTAK – TEYDEB co-funded studies
  • Publications, patents, and technology transfer initiatives
Through these partnerships, Çetinkaya Pharmaceuticals contributes to transferring academic knowledge into industry while generating innovation at international standards.

Turkey’s Firsts – Çetinkaya Pharmaceuticals & Laboratories • First private-sector BSL-3 and BSL-2 laboratory infrastructure in the pharmaceutical field

Enables high-risk pathogen research and advanced viral/bacterial R&D operations.

• Dedicated Equine Facility for Vaccine and Antiserum Projects

Among Türkiye’s first private-sector hyperimmune serum production units.

• Comprehensive biotechnology characterization capacity

Mass spectrometry, sequencing technologies, advanced chromatography systems, and biological activity assays allow end-to-end development of biotechnological products in-house.

Supported R&D Programs

Çetinkaya Pharmaceuticals conducts projects supported by TÜBİTAK – TEYDEB and international funding mechanisms. Completed programs include:
  • First-ever pharmaceutical raw materials manufactured in Türkiye
  • Locally formulated sterile pharmaceutical products
  • New-generation biotechnological platforms
Çetinkaya also provides services to multinational generic companies including CTD-format dossier preparation, process development, and technology transfer.

Patents and Intellectual Property

For newly developed formulations, processes, and biotechnological platforms, applications have been filed before:
  • The Turkish Patent and Trademark Office
  • EPO
  • USPTO
Several R&D outputs have already been transformed into commercialized patents.

Compliance with International Standards

All processes are conducted in alignment with:
  • EU-GMP / PIC/S GMP
  • ICH guidelines
  • GLP quality assurance
  • 21 CFR Part 11 data integrity requirements

Conclusion: A Growing R&D Ecosystem Powered by University–Industry Collaboration

Strengthened by the strategic vision of Eliz İlaç, Çetinkaya Pharmaceuticals and Laboratories is rapidly expanding as an R&D and innovation platform that:
  • Places university collaboration at its core,
  • Focuses on high value-added products,
  • Enhances regional biotechnology capacity,
  • Competes at international standards.



Elizilac.com
Telefon
WhatsApp